Table 1.
Characteristic | Patients, No. (%) |
---|---|
Age, median (range), y | 64 (50–76) |
Sex | |
Male | 10 (45) |
Female | 12 (55) |
Race | |
White | 21 (95) |
Black | 1 (5) |
ECOG performance status | |
0 | 14 (64) |
1 | 8 (36) |
Serum CA 19-9, median (range), U/mL | 122 (0–910) |
Tumor diameter, median (range), mm | 30 (16–49) |
Radiographic tumor-vessel interfacea | |
Vein onlyb | 6 (27) |
<180° | 0 (0) |
≥180° | 6 (27) |
Artery onlyc | 3 (14) |
<180° | 3 (14) |
≥180° | 0 (0) |
Artery and veinb,c | 13 (59) |
Artery <180°, vein <180° | 6 (27) |
Artery <180°, vein ≥180° | 6 (27) |
Arteryd ≥180°, vein <180° | 1 (5) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate antigen.
On central review, all vessels were patent, and no patient had a radiologic interface between the tumor and 180° or more of the superior mesenteric artery.
Portal vein and/or superior mesenteric vein.
Superior mesenteric artery, hepatic artery, or celiac trunk.
Common hepatic artery.